Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus.

In: The Journal of rheumatology · 1991 · vol. 18(2) , pp. 280–2 · PMID:2023224 · W124010063
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by qwen3.7-flash, 2026-08-13

Danazol successfully treated severe autoimmune hemolytic anemia in a patient with systemic lupus erythematosus who failed other therapies, indicating its potential as a therapeutic option for this condition.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We describe a patient with systemic lupus erythematosus (SLE) complicated by severe autoimmune hemolytic anemia. Therapy with corticosteroids, splenectomy, azathioprine, chlorambucil, and intravenous immunoglobulin was unsuccessful. She responded to danazol, however, with maintenance of her hemoglobin and reductions in her transfusion and corticosteroid requirement. Thus, danazol may represent an important therapeutic option in the treatment of autoimmune hemolytic anemia.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

SciLite annotations

chemicals 7
danazol corticosteroid azathioprine chlorambucil danazol corticosteroid danazol

Source provenance

openalex
last seen: 2026-05-10T10:28:17.326268+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0 · commercial use OK